Smith & Nephew plc (LON:SN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Smith & Nephew plc (LON:SN) has been given a consensus rating of “Moderate Buy” by the six research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is GBX 1,444.40 ($17.58).

A number of research firms recently issued reports on SN. Barclays reissued an “underweight” rating and set a GBX 1,200 ($14.60) target price on shares of Smith & Nephew in a research report on Monday, October 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew in a research report on Thursday, July 20th.

Smith & Nephew Stock Up 2.0 %

SN opened at GBX 981.60 ($11.94) on Monday. The firm has a 50 day moving average price of GBX 998.77 and a 200 day moving average price of GBX 1,133.76. The company has a market cap of £8.57 billion, a PE ratio of 4,674.29, a price-to-earnings-growth ratio of 0.37 and a beta of 0.40. Smith & Nephew has a 1 year low of GBX 887 ($10.79) and a 1 year high of GBX 1,316.75 ($16.02). The company has a debt-to-equity ratio of 58.09, a quick ratio of 0.84 and a current ratio of 2.19.

Insiders Place Their Bets

In related news, insider Roberto Quarta purchased 5,513 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was purchased at an average price of GBX 1,067 ($12.98) per share, for a total transaction of £58,823.71 ($71,579.11). 0.22% of the stock is owned by company insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.